{"title":"Analysis suggests risk of suicidal ideation associated with semaglutide","authors":"","doi":"10.1002/pu.31236","DOIUrl":null,"url":null,"abstract":"<p>An analysis of a global database documenting adverse drug reactions has detected a disproportional occurrence of suicidal ideation associated with use of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide. This association was not present with use of the GLP-1 receptor agonist liraglutide or with other medications used to treat type 2 diabetes or obesity. Study results were published online Aug. 20, 2024 in <i>JAMA Network Open</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 12","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
An analysis of a global database documenting adverse drug reactions has detected a disproportional occurrence of suicidal ideation associated with use of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide. This association was not present with use of the GLP-1 receptor agonist liraglutide or with other medications used to treat type 2 diabetes or obesity. Study results were published online Aug. 20, 2024 in JAMA Network Open.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
